Log In
BCIQ
Print this Print this
 

OXB-302

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionLentiVector-based CAR-T cell therapy targeting 5T4 tumor antigen
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today